NCT00732784 - Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

November 30, 2012

Study Completion Date

December 31, 2012

Conditions

Healthy

Interventions

DRUG

Imatinib mesylate

Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)

DIETARY_SUPPLEMENT

calcium carbonate

Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)

Trial Locations (1)

15232

University of Pittsburgh Cancer Institute / Clinical and Translational Research Center (Hillman Cancer Center location), Pittsburgh